The distribution of BRCA1/2 mutations identified differed by breast cancer subtype, with BRCA1 mutations predominated among TNBC (94%, 15/16) while BRCA2 mutations predominated among patients with HR and/or HER2-positive MBC (75%, 12/16). Here, ERBB2 is linked to breast carcinoma.